Theranos-Style Fraud Has Become the Norm: Tech Needs a Reckoning on Integrity

An article that sparked heated discussion on Hacker News put forward a stinging verdict: Theranos-style fraud is no longer an occasional business scandal—it has become the industry norm. This view deserves serious attention not because it is sensational, but because it points to a structural distortion of incentives in the venture ecosystem: the rewards of lying far outweigh the costs of lying.

Theranos Is Not an Isolated Case, but a Template

The story of Elizabeth Holmes has been told so many times that people easily treat it as a fable about personal charisma and moral decay. But a consensus that repeatedly emerged in the HN discussion is this: Theranos got as far as it did not because of Holmes's deception alone, but because of an entire system that was willing to believe, willing to endorse, and willing to let things pass.

The board included former secretaries of state and retired generals, the media happily reported the "female Steve Jobs" narrative, and investors actively loosened their diligence. According to discussion in the HN comments, this structure is not unique to Theranos—from blood testing to AI medical diagnosis, from biotech to autonomous driving, valuation-driven narrative packaging plays out again and again across sectors. When a company's main asset is a "story" rather than a verifiable product, the soil for fraud has already been laid.

The real danger signal is this: after Theranos collapsed, the industry did not establish any effective defense mechanism. There was no new regulatory framework, no systematic soul-searching by investment institutions—only a scapegoat sent to prison, after which the industry continued following the same script to look for the next unicorn.

Theranos's core business was the claim that it could complete hundreds of tests using a single drop of finger-prick blood, and its proprietary device "Edison" was promoted as a revolutionary technology that would upend traditional laboratories. However, the company never published independently verified clinical data in peer-reviewed journals, nor did it allow outside experts to inspect the device. A 2015 investigative report by The Wall Street Journal revealed that it could in fact complete only a few tests, and that the accuracy of the results was questionable. The U.S. CMS subsequently revoked its clinical laboratory certification, and the company dissolved in 2018. The reason this case became a template is that it demonstrated how the combination of "technology black box + celebrity board + media narrative" can long conceal the unverifiability of core technology.

Why the Cost of Lying Is So Low

The key to understanding this problem is to see clearly how incentives are distributed along the venture chain.

On the Founder's Side: Asymmetric Bets

Entrepreneurs take other people's money and gamble on their own upside. If the story works, the reward is wealth and prestige dozens of times over; if it fails, the worst outcome is usually that the company closes and the individual moves to a different track and starts over. This bet structure naturally encourages exaggeration—especially in a culture where "fake it till you make it" is celebrated as an entrepreneurial virtue.

"Fake it till you make it" is widely regarded in Silicon Valley startup culture as a reasonable form of strategic exaggeration. Its logic is that startups have limited resources and must first use a vision to attract talent and capital, then gradually deliver the product. This culture blurs the boundary between "overpackaging" and "deliberate fraud." In the Theranos case, Holmes's defense team tried precisely to categorize her behavior within this cultural tradition, but prosecutors pointed out that when the company knew the technology could not be realized yet still provided patients with erroneous test results, it had already crossed the legal red line of fraud. This cultural background makes investors and the media inclined to grant "all startups are like this" tolerance when faced with exaggerated claims, thereby reducing the probability that fraud is identified early.

On the Investor's Side: A Tacit Agreement of Collective Exemption

The VC business model determines that they do not need to be responsible for every failure—they only need one sufficiently large winner to cover all losses. This means that during the diligence stage, investors have an incentive not to dig deeply into details that might puncture the narrative—because puncturing it might instead cause them to miss the next big opportunity. Someone in the HN discussion sharply pointed out that many investors were not deceived; they selectively chose not to verify.

VC's limited partnership structure determines that fund managers mainly profit from management fees and carried interest, with LPs bearing most of the loss from any single failed project, while the excess returns from successful projects are shared with GPs. This asymmetry further amplifies the incentive for "selective non-verification": the GP's incentive is to find winners that can go public or be acquired at a high price, not to ensure that every project can withstand technical audit. In addition, co-investment mechanisms and FOMO (fear of missing out) make investors inclined to follow the judgment of lead investors, forming collective endorsement and further weakening the motivation for independent due diligence.

On the Media and Platform Side: Collusion in Narrative

Tech media relies on "change the world" stories to gain traffic, and platforms rely on hot topics to gain attention. When a founder is packaged as an idol of the era, skeptical voices are often drowned out by praise for the "vision." Part of the reason Theranos's fall was so shocking is precisely that almost all mainstream narratives had previously endorsed it.

Who Bears the Cost of Fraud Becoming the Norm

On the surface, Theranos's victims were investors and employees. But the deeper cost falls on the trust foundation of the entire industry.

When fraud becomes the norm, honest companies are instead at a competitive disadvantage—they are unwilling to exaggerate clinical data or fabricate user growth, so they fall behind those opponents who dare to boast in terms of financing pace and media volume. This is a mechanism of bad money driving out good. Someone in the HN comments mentioned that teams genuinely doing hard tech, which requires long-cycle verification, often find it hardest to obtain patient capital in the current financing environment.

Ultimately, ordinary users and patients pay the price. Theranos's testing devices produced incorrect blood results—this is not an abstract business failure, but a concrete health risk. When similar narrative packaging appears in fields such as AI healthcare and autonomous driving, the same risks will reappear in different forms.

How to Identify the Next Theranos

Some heuristic judgments formed in the HN discussion are worth using as a checklist for practitioners:

• Can the core technology be independently verified? If a company refuses to let outside experts inspect its core claims, that itself is the biggest red flag. Theranos's avoidance of peer review now looks in hindsight like the most obvious signal.
• Does narrative density far exceed product density? When a company's media exposure, founder story, and vision speeches far exceed deliverable products and third-party data, be on alert.
• Is the board composed of domain experts? A celebrity board sounds glamorous, but if its members lack the ability to judge the core technology, their endorsement is merely decoration.
• Are there "undiscussable" internal forbidden zones? Whether employees can openly question the technology roadmap is a touchstone of organizational health. Theranos's suppression of internal skeptics was an accelerator of its collapse.

Structural Repair Matters More Than Moral Condemnation

Treating Theranos as a moral story about greed and vanity may make people feel comfortable, but it does not help prevent the next occurrence. What really needs to change is the incentive structure itself.

Feasible directions include: investment institutions establishing independent third-party technical due diligence mechanisms instead of relying on the intuition of internal partners; regulators setting more upfront verification thresholds for claims involving personal safety; and the media exercising restraint toward "vision" when reporting on early-stage companies. None of this is new, but the pessimism revealed by the HN discussion is that after Theranos, almost none of these changes happened.

Fraud has become the norm not because human nature has become worse, but because the system has not priced honesty. In this sense, the reckoning for Theranos-style fraud will not come from a single trial, but only from a redesign of incentive mechanisms across the entire industry.

This article is based on relevant discussions on Hacker News; the views belong to the original discussion participants.

One-line Summary

Theranos-style fraud has become the norm, rooted in distorted incentives in the venture ecosystem rather than individual moral problems.

Paragraph Summary

Based on a Hacker News discussion, the article points out that Theranos-style fraud is not an isolated case but a product of structural incentive distortion in the venture ecosystem. Founders gamble other people's capital on personal gains, investors selectively avoid verification because of their business model, and the media relies on "change the world" narratives to gain traffic. The collusion of these three parties allows the soil for fraud to persist. The normalization of fraud leads to bad money driving out good, putting honest companies at a disadvantage, and ultimately ordinary users and patients bear the cost. The article proposes a checklist for identifying the next Theranos, including verifiability of core technology, comparison of narrative and product density, board professionalism, and room for internal questioning. It concludes that moral condemnation is useless; only redesigning incentive mechanisms—such as third-party technical due diligence, upfront regulatory verification, and media restraint—can reverse the system's failure to price honesty.